Key facts
- Notable investors include Chengdu High-Tech Investment, Orinno Capital, Chengdu New Economy Venture Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Anjianlikang Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Anjianlikang Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Anjianlikang Biotechnology
Manufacturer of small-molecule inhibitors intended to advance therapeutic innovation in healthcare. The company offers research-driven drug development expertise and a focus on ENDOD1 inhibitor technology, enabling pharmaceutical enterprises and medical researchers to enhance treatment efficacy and accelerate clinical applications.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2025
- Ownership
- Privately Held (backing)
Anjianlikang Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Anjianlikang Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Anjianlikang Biotechnology in its N-PORT filings yet. We sweep new filings monthly.